Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate

Journal of Chemotherapy

Volumn 18, Issue 5, 2006, Pages 485-489

  Wagenlehner, Florian M E ^a   Lunz, J C ^b   Kees, F ^b   Wieland, W ^b   Naber, K G ^a  

^a Urologische Klinik   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Chronic bacterial prostatitis; Moxifloxacin; Pharmacokinetics; Prostatic tissue concentrations; Serum concentrations

Indexed keywords

MOXIFLOXACIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PROSTATE; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION;

EID: 33751162097     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.5.485     Document Type: Article

References (26)

1. Schaeffer AJ. Prostatitis: US perspective. Int J Antimicrob Agents 1999;11(3-4):205-11; discussion 213-6.
2. (NIDDK). Chronic Prostatitis Workshop. Bethesda, MD; 7-8 December, 1995.
3. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection 1991;19 Suppl 3:S119-25.
4. Schneider H, Ludwig M, Hossain HM, Diemer T, Weidner W. The 2001 Giessen Cohort Study on patients with prostatitis syndrome-an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia 2003;35(5):258-62.
5. Skerk V, Krhen I, Schonwald S, Cajic V, Markovinovic L, Roglic S, et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents 2004;24 Suppl 1:S53-6.
6. Krieger JN, Riley DE. Chronic prostatitis: Charlottesville to Seattle. J Urol 2004;172(6 Pt 2):2557-60.
7. Badalyan RR, Fanarjyan SV, Aghajanyan IG. Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Andrologia 2003;35(5):263-5.
8. Stamey TA, Meares EM, Jr., Winningham DG. Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol 1970;103(2):187-94.
9. Wagenlehner FM, Naber KG. Antimicrobial treatment of prostatitis. Expert Rev Anti Infect Ther 2003;1(2):275-82.
10. Bjerklund Johansen TE, Gruneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998;34(6):457-66.
11. Naber KG, Adam D. Classification of fluoroquinolones. Int J Antimicrob Agents 1998;10(4):255-7.
12. Bayer. Fachinformation Avelox (Zusammenfassung der Produkteigenschaften); 2002.
13. MacGowan AP. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opinion on Investigational Drugs 1999;8(2):181-199.
14. Lapatschek M, Hartinger, A. Microbial diversity and resistance of pathogens in prostatitis. In: 12th scientific meeting of the European Society of Chemotherapy. 2006 March 16-19, 2006; Aachen, Germany; 2006. p. 39.
15. Png JC, Tan E, Foo KT, Li MK, Cheng C, Rekhraj IR. A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. Br J Urol 1997;79(5):781-4.
16. Kees F, Naber KG, Schumacher H, Grobecker H. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue. Chemotherapy 1988;34(6):437-43.
17. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001;17(4):331-41.
18. Naber K, Madsen, PO. Antibiotics: Basic concepts. In: Nickel J, editor. Textbook of prostatitis. Oxford, UK: Isis Medical Media; 1999. p. 83-94.
19. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998;42(8):2060-5.
20. Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999;43(6):1508-10.
21. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999;43 Suppl B:83-90.
22. Naber KG, Sorgel F. Antibiotic therapy-rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003;35(5):331-5.
23. Gehanno P, Darantiere S, Dubreuil C, Chobaut JC, Bobin S, Pages JC, et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002;49(5):821-6.
24. Esposito S, Noviello S, D'Errico G, Motta G, Passali D, Aimoni C, et al. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. J Antimicrob Chemother 2006;57(4):789-92.
25. Breilh D, Jougon J, Djabarouti S, Gordien JB, Xuereb F, Velly JF, et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J Chemother 2003;15(6):558-62.
26. Nickel JC, Olson ME, Costerton JW. Rat model of experimental bacterial prostatitis. Infection 1991;19 Suppl 3:S126-30.